---
annotations:
- type: Pathway Ontology
  value: signaling pathway
- type: Pathway Ontology
  value: kinase mediated signaling pathway
authors:
- ReactomeTeam
- Anwesha
- Ryanmiller
description: The RAS-RAF-MEK-ERK pathway regulates processes such as proliferation,
  differentiation, survival, senescence and cell motility in response to growth factors,
  hormones and cytokines, among others. Binding of these stimuli to receptors in the
  plasma membrane promotes the GEF-mediated activation of RAS at the plasma membrane
  and initiates the three-tiered kinase cascade of the conventional MAPK cascades.  GTP-bound
  RAS recruits RAF (the MAPK kinase kinase), and promotes its dimerization and activation
  (reviewed in Cseh et al, 2014; Roskoski, 2010; McKay and Morrison, 2007; Wellbrock
  et al, 2004).  Activated RAF phosphorylates the MAPK kinase proteins MEK1 and MEK2
  (also known as MAP2K1 and MAP2K2), which in turn phophorylate the proline-directed
  kinases ERK1 and 2 (also known as MAPK3 and MAPK1) (reviewed in Roskoski, 2012a,
  b; Kryiakis and Avruch, 2012).  Activated ERK proteins may undergo dimerization
  and have identified targets in both the nucleus and the cytosol; consistent with
  this, a proportion of activated ERK protein relocalizes to the nucleus in response
  to stimuli (reviewed in Roskoski 2012b; Turjanski et al, 2007; Plotnikov et al,
  2010; Cargnello et al, 2011).  Although initially seen as a linear cascade originating
  at the plasma membrane and culminating in the nucleus, the RAS/RAF MAPK cascade
  is now also known to be activated from various intracellular location.  Temporal
  and spatial specificity of the cascade is achieved in part through the interaction
  of pathway components with numerous scaffolding proteins (reviewed in McKay and
  Morrison, 2007; Brown and Sacks, 2009). <br> The importance of the RAS/RAF MAPK
  cascade is highlighted by the fact that components of this pathway are mutated with
  high frequency in a large number of human cancers.  Activating mutations in RAS
  are found in approximately one third of human cancers, while ~8% of tumors express
  an activated form of BRAF (Roberts and Der, 2007; Davies et al, 2002; Cantwell-Dorris
  et al, 2011).  View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=5673001
  Reactome].
last-edited: 2021-01-25
organisms:
- Homo sapiens
redirect_from:
- /index.php/Pathway:WP2735
- /instance/WP2735
schema-jsonld:
- '@context': https://schema.org/
  '@id': https://wikipathways.github.io/pathways/WP2735.html
  '@type': Dataset
  creator:
    '@type': Organization
    name: WikiPathways
  description: The RAS-RAF-MEK-ERK pathway regulates processes such as proliferation,
    differentiation, survival, senescence and cell motility in response to growth
    factors, hormones and cytokines, among others. Binding of these stimuli to receptors
    in the plasma membrane promotes the GEF-mediated activation of RAS at the plasma
    membrane and initiates the three-tiered kinase cascade of the conventional MAPK
    cascades.  GTP-bound RAS recruits RAF (the MAPK kinase kinase), and promotes its
    dimerization and activation (reviewed in Cseh et al, 2014; Roskoski, 2010; McKay
    and Morrison, 2007; Wellbrock et al, 2004).  Activated RAF phosphorylates the
    MAPK kinase proteins MEK1 and MEK2 (also known as MAP2K1 and MAP2K2), which in
    turn phophorylate the proline-directed kinases ERK1 and 2 (also known as MAPK3
    and MAPK1) (reviewed in Roskoski, 2012a, b; Kryiakis and Avruch, 2012).  Activated
    ERK proteins may undergo dimerization and have identified targets in both the
    nucleus and the cytosol; consistent with this, a proportion of activated ERK protein
    relocalizes to the nucleus in response to stimuli (reviewed in Roskoski 2012b;
    Turjanski et al, 2007; Plotnikov et al, 2010; Cargnello et al, 2011).  Although
    initially seen as a linear cascade originating at the plasma membrane and culminating
    in the nucleus, the RAS/RAF MAPK cascade is now also known to be activated from
    various intracellular location.  Temporal and spatial specificity of the cascade
    is achieved in part through the interaction of pathway components with numerous
    scaffolding proteins (reviewed in McKay and Morrison, 2007; Brown and Sacks, 2009).
    <br> The importance of the RAS/RAF MAPK cascade is highlighted by the fact that
    components of this pathway are mutated with high frequency in a large number of
    human cancers.  Activating mutations in RAS are found in approximately one third
    of human cancers, while ~8% of tumors express an activated form of BRAF (Roberts
    and Der, 2007; Davies et al, 2002; Cantwell-Dorris et al, 2011).  View original
    pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=5673001 Reactome].
  keywords:
  - 'SPRED3 '
  - 'CNKSR1 '
  - activated
  - 'p-6Y,Y1112-ERBB2 '
  - p21 RAS:GTP:RAS GAPs
  - p21RAS:GTP:p-S621
  - inactive RAFS:YWHAB
  - 'KSR2 '
  - 'UBC(381-456) '
  - 'High affinity binding complex dimers of cytokine receptors using Bc, inactive
    JAK2, p-(Y593,628)-Bc:p(427,349,350)-SHC1 '
  - PAQR3
  - 'APBB1IP '
  - Factor 1 Receptor
  - ATP
  - 'FGB '
  - Fc epsilon receptor
  - RAS:GTP:homo/heterodimerized RAF complex
  - 'EGF '
  - single mechanism
  - 'RGL1 '
  - 'PSMB5 '
  - 'PSMA7 '
  - kinase activity
  - 'MAP2K1 F53Y '
  - 'UBC(457-532) '
  - 'p-S576 ARAF '
  - complexes
  - 'SPTA1 '
  - 'DUSP4 '
  - MAPK:single
  - 'MAP2K1 '
  - 'IL17RD '
  - 'GFRA4 '
  - 'p-6Y-FRS2 '
  - 'KITLG-1(26-190) '
  - Interleukin-2 family
  - SPRED dimer
  - 'FGF8-1 '
  - 'FGF17-1 '
  - 'p-Y-SHC3 '
  - 'p-T287-CAMK2B '
  - 'MAP2K1 Y130C '
  - 'RPS27A(1-76) '
  - 'p-Y-SHC2 '
  - 'PSMD11 '
  - 'MAP2K1 P124S '
  - PPP5C
  - RAS GEFs
  - HRAS:GTP:RAL GDS
  - 'p-5Y-LAT-2 '
  - 'RAF:scaffold:p-2S '
  - MAPK2K2 heterodimer
  - p21RAS:GTP:homo/heterodimerized RAF complex:RAF dimer inhibitors
  - 'p-T,Y MAPKs '
  - cytosolic MAPK DUSPs
  - 'ub-BRAP '
  - 'CNKSR2 '
  - 'SPTBN4 '
  - PTPN7:p-T-MAPK
  - 'PSMB9 '
  - 'S-Farn-Me-PalmS KRAS4A '
  - MAPK12
  - kinases
  - Pi
  - 'p-5Y-RET '
  - 'dabrafenib mesylate '
  - RAF dimer inhibitors
  - 'p-T184-RASGRP1 '
  - 'PPP2R1B '
  - 'p-S445,T599,S602,S729 BRAF '
  - (TRKA)
  - 'PSMA3 '
  - 'MARK3 '
  - 'FGF2(10-155) '
  - 'CUL3 '
  - dimers
  - ERBB2 becomes activated by forming a heterodimer with another ligand-activated
    EGFR family member, either EGFR, ERBB3 or ERBB4, which is accompanied by dissociation
    of chaperoning proteins HSP90 and CDC37 (Citri et al. 2004), as well as ERBB2IP
    (Borg et al. 2000) from ERBB2. ERBB2 heterodimers function to promote cell proliferation,
    cell survival and differentiation, depending on the cellular context. ERBB2 can
    also be activated by homodimerization when it is overexpressed, in cancer for
    example. <br><br>
  - 'p-S311,S406 KSR1 '
  - 'DUSP6 '
  - MAP2K:MAPK:single
  - 'SPTB '
  - high kinase activity
  - RAF:scaffold:p-2S
  - 'WDR83 '
  - RAF
  - homo/heterodimers
  - 'PSMD6 '
  - 'LAMTOR2 '
  - MAP2K:p-2T MAPK
  - Signaling by Insulin
  - 'GRIN1 '
  - 'UBC(153-228) '
  - 'p-S445,S729-BRAF '
  - 'EREG(60-108) '
  - 'RALGDS '
  - RAF1
  - 'ARRB1 '
  - 'RASAL2 '
  - 'PSMD9 '
  - 'p-T287-CAMK2D '
  - 'FGF22 '
  - WDR83:LAMTOR2:LAMTOR3
  - 'ulixertinib '
  - MAP2K:MAPK:dual
  - 'PEBP1 '
  - MAP2K:MAPK complex
  - 'PPP2CB '
  - 'p-11Y-PDGFRA '
  - 'S-Farn-Me-2xPalmS HRAS '
  - RAS:GTP:activated
  - 'GalNAc-T178-FGF23(25-251) '
  - Signaling by FGFR1
  - and dimers:PEA15
  - dephosphorylated
  - dual mechanism
  - 'BRAF K601N '
  - 'MAP2K2 N126D '
  - inhibitors
  - GTP
  - S-Farn-Me-2xPalmS
  - 'NEFL '
  - 'RASGRF1 '
  - 'MAP2K1 K57T '
  - 'NRTN '
  - 'p-Y1234,Y1235,Y1349,Y1356-MET '
  - RAF:YWHAB dimer
  - 'MAP2K1 F53L '
  - SPRED dimer:ub-NF1
  - 'PSMD14 '
  - p-T,Y MAPKs
  - 'DLG3 '
  - 'p-Y194,Y195,Y272-SHC1-3 '
  - 'PSMC6 '
  - 'SPTBN2 '
  - p21 RAS:GTP:ub-BRAP
  - 'p-5Y,S1119-TEK '
  - (IGF1R)
  - 'MAP2K1 G128D '
  - 'PSMB7 '
  - 'MAP2K2 L46F '
  - 'PIK3R1 '
  - p21RAS:GTP:activated
  - 'PSME1 '
  - This pathway describes some of the key interactions that assist in the process
    of platelet and leukocyte interaction with the endothelium, in response to injury.
  - 'PSMB3 '
  - NF1(2-2839)
  - 'MAP2K1 V60E '
  - p-S338,Y341,T491,S494,S621 RAF1
  - 'MAP2K1 D67N '
  - 'PPP2R5C '
  - 'ARRB2 '
  - 'PPP1CC '
  - 'p-T183,Y185-MAPK12 '
  - YWHAB dimer
  - 'p-Y341,T491,S494,S621 RAF1 '
  - 'BRAF G534R '
  - 'LAMTOR3 '
  - 'DUSP9 '
  - Neurotransmitter
  - 'PPP2R1A '
  - IL17RD:p-2S
  - 'PIK3CA '
  - 'p-Y427-SHC1 '
  - Other interleukin
  - 'L-Glu '
  - 'p-T202-MAPK3 '
  - 'Neuregulins '
  - BRAF mutants
  - 'UBC(229-304) '
  - 'UBC(77-152) '
  - 'RASAL1 '
  - Insulin-like Growth
  - 'p-Y239,Y240,Y317-SHC1-2 '
  - 'BRAF 599dupT '
  - 'SYNGAP1 '
  - homo/heterodimer:PEBP1
  - 'DAG '
  - 'FGF23(25-251) '
  - 'SPRED1 '
  - PI3K
  - 'BTC(32-111) '
  - 'p-12Y-PDGFRB '
  - 'PTPRA '
  - Signaling by FGFR3
  - 'p-S621-RAF1 '
  - 'DLG4 '
  - 'CSK '
  - 'ANGPT1 '
  - 'DUSP2 '
  - 'JAK2 '
  - PEBP1
  - KBTBD7:CUL3:RBX1
  - 'p-5Y-FGFR4 '
  - Cell surface
  - 'IL2RG '
  - RAL GDS proteins
  - 'PIK3R2 '
  - 'UBB(153-228) '
  - 'p-6Y-ERBB2 heterodimers '
  - 'PSMB11 '
  - p21 RAS:GTP
  - 'PSPN '
  - 'BRAF V600E V47_M438del '
  - p21
  - 'GFRA2 '
  - RAF activating
  - 'p-T185-MAPK1 '
  - 'GRIN2B '
  - H2O
  - S-GCC
  - 'DLG2 '
  - 'p-6Y-FGFR3c '
  - 'DUSP1 '
  - 'trametinib '
  - 'HGF(32-494) '
  - transmission
  - PTPN7:p-T,Y-MAPK
  - PTPN3
  - 'PSMC4 '
  - 'BRAF V600E '
  - complex
  - 'MAP2K1 D67Y '
  - inactive RAFs
  - 'Mg2+ '
  - MAPK inhibitors
  - 'PSMC2 '
  - 'FGF18 '
  - 'Gly '
  - 'FN1(32-2386) '
  - IL17RD
  - 'FGF1 '
  - Signaling by ERBB4
  - 'p-S311 KSR1 '
  - 'MAP2K2 Y134C '
  - RAF:scaffold:MAP2K:MAPK complex:dual mechanism MAP2K inhibitors
  - inactive RAFs:YWHAB
  - 'UBB(77-152) '
  - DAP12 interactions
  - 'PSME2 '
  - 'KL-2 '
  - 'HGF(495-728) '
  - 'RBX1 '
  - 'BRAF K499E '
  - 'ub-NF1(2-2839) '
  - homo/heterodimer
  - 'PSME4 '
  - 'FGG '
  - 'TGFA(24-98) '
  - 'TLN1 '
  - 'KSR1 '
  - 'FGF16 '
  - 'p-T185,Y187-MAPK1 '
  - 'SHFM1 '
  - 'PSMD12 '
  - p-2S,T MAP2K1:p-2S
  - 'MAPK3 '
  - variant dimer
  - 'p-S311,Y552 KSR1 '
  - 'PSMA2 '
  - signaling
  - mechanism MAPK
  - 'MAP2K1 K57N '
  - BRAF inhibitors
  - 'p-Y1172,Y1226-ERBB4 JM-A CYT-2 isoform '
  - 'YWHAB '
  - 'ACTN2 '
  - 'RASA4 '
  - neurite out-growth
  - 'p-Y-IRS1 '
  - Cell Receptor (BCR)
  - 'p-Y349,Y350,Y427-SHC1 '
  - p21 RAS:GTP:BRAP
  - variants
  - 'MAP2K1 Q56P '
  - 'Phosphorylated ERBB2:ERBB4cyt2 heterodimers '
  - p21 RAS:GDP
  - 'BRAF L485F '
  - 'GTP '
  - 'MAP2K1 E44_E57del '
  - Signaling by ERBB2
  - 'Activated FGFR2c homodimer bound to FGF '
  - MAP3K11
  - Interleukin-5 and
  - 'PSMB8 '
  - 'PSMB1 '
  - p-T183,Y185-MAPK12
  - 'MAP2K2 P128Q '
  - 'V600E BRAF V169_D380del '
  - 'PDGFB(82-241) '
  - 'SPTBN5 '
  - 'DUSP5 '
  - 'MAP2K1 G128V '
  - 'S-Farn-Me PalmS NRAS '
  - 'BRAF V600E  V169_M438del '
  - 'RASAL3 '
  - MAPK monomers and
  - 'p-Y-JAK1 '
  - 'PSMD3 '
  - 'p-S259,S621-RAF1 '
  - MRAS:GTP:SHOC2:PP1
  - 'p-S365,S445,S729 BRAF '
  - 'IL2 '
  - 'p-S222,S226-MAP2K2 '
  - 'p-7Y,Y1112-ERBB2 '
  - 'Mn2+ '
  - 'PAQR3 '
  - 'p-T,Y MAPK dimers '
  - 'PSMD5 '
  - 'PSMA8 '
  - p21RAS:GTP:dephosphorylated RAF1 homo/heterodimer
  - GDP
  - 'p-8Y-FGFR1c '
  - NCAM signaling for
  - mutants
  - 'p-5Y-FRS3 '
  - 'SOS1 '
  - 'p-T133-RASGRP3 '
  - BRAF inhibitors:high
  - 'MAP2K2 F57C '
  - 'p-7Y-KIT '
  - 'RASGRF2 '
  - 'Autophosphorylated FLT3 '
  - 'PEA15 '
  - 'AREG(101-187) '
  - 'D-Ser '
  - 'p-S214,S576 ARAF '
  - Signaling by EGFR
  - activated RAF
  - 'CAMK2G '
  - MAP2K1 and MAP2K2
  - p-S311 KSR1:MARK3
  - interactions at the
  - 'MyrG,p-Y530-SRC '
  - RAF/MAPK scaffolds
  - 'FGF9 '
  - dual mechanism MAPK
  - 'GDP '
  - 'RASGEF1A '
  - BRAP:KSR1:MARK3
  - RAF:scaffold:MAP2K:MAPK complex
  - 'RASGRP4 '
  - 'S-Farn-Me KRAS4B '
  - 'SHOC2 '
  - 'IQGAP1 '
  - 'VWF(23-763) '
  - hyperphosphorylated
  - 'PSMB6 '
  - MAP2Ks:p-T,Y MAPKs
  - 'p-6Y-EGFR '
  - 'CAMK2B '
  - Signaling by SCF-KIT
  - 'PPP1CB '
  - 'SPRED2 '
  - 'MAP2K2 '
  - 'PTPN3 '
  - 'DAB2IP '
  - 'MAP2K1 F53C '
  - 'ITGA2B(32-1039) '
  - 'MAP2K1 E203K '
  - PAQR3:inactive RAFs
  - 'NF1(2-2839) '
  - 'DUSP16 '
  - BRAP
  - SPRED dimer:NF1
  - Signaling by PDGF
  - In cells expressing ERBB2 and ERBB3, ERBB3 activated by neuregulin NRG1 or NRG2
    binding (Tzahar et al. 1994) forms a heterodimer with ERBB2 (Pinkas-Kramarski
    et al. 1996, Citri et al. 2004). ERBB3 is the only EGFR family member with no
    kinase activity, and can only function in heterodimers, with ERBB2 being its preferred
    heterodimerization partner. After heterodimerization, ERBB2 phosphorylates ten
    tyrosine residues in the C-tail of ERBB3, Y1054, Y1197, Y1199, Y1222, Y1224, Y1260,
    Y1262, Y1276, Y1289 and Y1328 (Prigent et al. 1994, Pinkas-Kramarski et al. 1996,
    Vijapurkar et al. 2003, Li et al. 2007) that subsequently serve as docking sites
    for downstream signaling molecules, resulting in activation of PI3K-induced AKT
    signaling and RAF/MAP kinase cascade. Signaling by ERBB3 is downregulated by the
    action of RNF41 ubiquitin ligase, also known as NRDP1. <br><br>
  - p-S445,T599,S602,S729 BRAF
  - p-T,Y MAPK dimers
  - 'FGF20 '
  - (FCERI) signaling
  - 'SPTBN1 '
  - nuclear MAPK DUSPs
  - 'PPP2CA '
  - 'PIK3CB '
  - 'FGF3 '
  - 'BRAF G469A '
  - 'F-actin '
  - 'RASA1 '
  - 'HS '
  - 'CALM1 '
  - 'PPP2R5A '
  - RAS GAPs
  - 'p-8Y-FGFR1b '
  - p-T,Y MAPK monomers
  - 'BRAF S467A '
  - 'SCH772984 '
  - Signaling by FGFR2
  - 'p-2S MAP2K homo/heterodimers '
  - 'PSMD13 '
  - 'PSMC5 '
  - 'MAP2K1 P124L '
  - 'RASA3 '
  - 'p-S459 PTPN3 '
  - 'PSMB4 '
  - 'p-S338,Y341,T491,S494,S621 RAF1 '
  - S-Farn-Me_2xPalmS
  - proteins
  - KSR1:MARK3:YWHAB
  - 'BRAF K601E '
  - 'p-T287-CAMK2G '
  - WDR83:LAMTOR2:LAMTOR3:activated RAF:MAP2K:MAPK complex
  - 'BRAF Q257R '
  - 'FGF4 '
  - 'GFRA1 '
  - 'EPGN(23-154) '
  - 'PSME3 '
  - 'MAPKs '
  - 'DUSP10 '
  - 'NCAM1 '
  - Signaling by NTRK1
  - 'PSMD8 '
  - 'PSMC1 '
  - 'MAPK1 '
  - p-2S MAP2K
  - 'MAP2K1 C121S '
  - and dimers
  - 'FGF10 '
  - 'FGA '
  - 'PSMC3 '
  - HRAS:GTP
  - ADP
  - 'PSMA4 '
  - 'EGF-like ligands '
  - 'p-T202,Y204-MAPK3 '
  - receptors and
  - MAP2K
  - 'p-Y420-FYN '
  - dimer
  - 'PSMA5 '
  - 'p-Y-SHC1 '
  - Signaling by Type 1
  - 'RANBP9 '
  - 'PSMB2 '
  - 26S proteasome
  - 'LRRC7 '
  - MAP2K:p-2T
  - 'PSMA6 '
  - 'FGF5-1 '
  - 'PSMD2 '
  - 'Phosphorylated ERBB2:ERBB4cyt1 heterodimers '
  - 'UBA52(1-76) '
  - 'JAK3 '
  - 'PDGFA-2 '
  - 'RAP1A '
  - PP2A
  - 'TAK-580 '
  - 'GRIN2D '
  - receptor
  - '''activator'''
  - 'UBC(533-608) '
  - In cells expressing both ERBB2 and EGFR, EGF stimulation of EGFR leads to formation
    of both ERBB2:EGFR heterodimers (Wada et al. 1990, Karunagaran et al. 1996) and
    EGFR homodimers. Heterodimers of ERBB2 and EGFR trans-autophosphorylate on twelve
    tyrosine residues, six in the C-tail of EGFR and six in the C-tail of ERBB2 -
    Y1023, Y1139, Y1196, Y1221, Y1222 and Y1248 (Margolis et al. 1989, Hazan et al.
    1990,Walton et  al. 1990, Helin et al. 1991, Ricci et al. 1995, Pinkas-Kramarski
    1996). Phosphorylated tyrosine residues in the C-tail of EGFR and ERBB2 serve
    as docking sites for downstream signaling molecules. Three key signaling pathways
    activated by ERBB2:EGFR heterodimers are RAF/MAP kinase cascade, PI3K-induced
    AKT signaling, and signaling by phospholipase C gamma (PLCG1). Downregulation
    of EGFR signaling is mediated by ubiquitin ligase CBL, and is shown under Signaling
    by EGFR.<br><br>
  - Ub
  - 'MyrG-p-Y419-SRC '
  - 'RASGRP1 '
  - '"receiver" RAF/KSR1'
  - 'p-Y349,Y350-SHC1 '
  - 'PSMD7 '
  - 'PSMA1 '
  - 'cobimetinib '
  - RAS:GTP:'activator'
  - 'p-ERBB4cyt1 homodimers '
  - MAPKs
  - KSR1:MARK3
  - 'PSMD4 '
  - 'p-S218,S222-MAP2K1 '
  - 'RAPGEF2 '
  - BRAF
  - 'ARTN '
  - p-2S MAP2K1:p-2S
  - 'PTPN7 '
  - 'Ca2+ '
  - 'PSMB10 '
  - 'KBTBD7 '
  - 'CAMK2D '
  - 'GDNF '
  - 'GRB2-1 '
  - PTPN7
  - 'p-Y364,Y418,Y536-IL2RB '
  - 'FGF6 '
  - PEA15
  - GM-CSF signaling
  - 'GFRA3 '
  - 'MAP2K2 C125S '
  - 'p-6Y-PTK2 '
  - p21 RAS:GTP:PI3K
  - postsynaptic signal
  - 'BRAP '
  - 'HBEGF(63-148) '
  - 'PSMD1 '
  - WDR83:LAMTOR2:LAMTOR3:activated RAF:p-2S MAP2K:p-T,Y MAPK complex
  - 'PSMD10 '
  - V600E BRAF splice
  - 'UBB(1-76) '
  - 'CAMK2A '
  - 'p-Y-IRS2 '
  - 'RGL3 '
  - 'PI(4,5)P2 '
  - p-S459
  - 'KL-1 '
  - 'MAP2K1 F53S '
  - 'FLT3LG '
  - 'KLB '
  - 'UBC(305-380) '
  - 'PDGFB (82-190) '
  - 'RASA2 '
  - Signaling by the B
  - 'VCL '
  - 'IL2RA '
  - p-S311,S406
  - 'p-S,218, S222,T292 MAP2K1 '
  - 'Autophosphorylated p-Y877-ERBB2 heterodimers '
  - 'p-6Y-FGFR3b '
  - Endothelial cells are tightly connected through various proteins, which regulate
    the organization of the junctional complex and bind to cytoskeletal proteins or
    cytoplasmic interaction partners that allow the transfer of intracellular signals.
    An important role for these junctional proteins in governing the transendothelial
    migration of leukocytes under normal or inflammatory conditions has been established.<p>
  - 'FGF19 '
  - 'ITGB3 '
  - 'UBC(1-76) '
  - 'MAP2K1 F53V '
  - RAS processing
  - 'BRAF V600E V47_D380del '
  - 'Activated FGFR2b homodimer bound to FGF '
  - 'DUSP7 '
  - Signaling by FGFR4
  - 'p-T286-CAMK2A '
  - In cells expressing ERBB2 and ERBB4, ligand stimulated ERBB4 can either homodimerize
    or form heterodimers with ERBB2 (Li et al. 2007), resulting in trans-autophosphorylation
    of ERBB2 and ERBB4 on C-tail tyrosine residues that will subsequently serve as
    docking sites for downstream signaling molecules, leading to activation of RAF/MAP
    kinase cascade and, in the case of ERBB4 CYT1 isoforms, PI3K-induced AKT signaling
    (Hazan et al. 1990, Cohen et al. 1996, Li et al. 2007, Kaushansky et al. 2008).
    Signaling by ERBB4 is downregulated by the action of WWP1 and ITCH ubiquitin ligases,
    and is shown under Signaling by ERBB4.
  - 'S-GGC MRAS '
  - 'p-Y317-SHC1-2 '
  - PTPN3:p-T183,Y185-MAPK12
  - 'DLG1 '
  - 'PSMF1 '
  - 'PPP2R5E '
  - vascular wall
  - 'UBC(609-684) '
  - p-S311
  - MAP2K1/2 inhibitors
  - 'PDGFA-1 '
  - 'SPTAN1 '
  - Interleukin-3,
  - PHB
  - 'MAP2K2 V35M '
  - mechanism MAP2K
  - MAP2Ks:MAPKs
  - 'MAP2K1 P124Q '
  - 'RAP1B '
  - 'p-S299,S302,T452,T455,S576 ARAF '
  - 'PPP2R5D '
  - 'PPP2R5B '
  - 'DUSP8 '
  - 'RGL2 '
  license: CC0
  name: RAF/MAP kinase cascade
seo: CreativeWork
title: RAF/MAP kinase cascade
wpid: WP2735
---